Tags : Puerto Rico

G1 Therapeutics and Boehringer Ingelheim Collaborate to Co-Promote Trilaciclib for

Shots: Boehringer to receive payments to cover start-up expenses and pre-approval initiatives for a successful commercial launch. Additionally, it receives mid-twenties percentage of net sales in the 1st yr. of commercialization, which decreases to a low double-digit/high single-digit percentage in the 2nd and 3rd year respectively G1 will book revenue in the selective territories and […]Read More